Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Digital 9 Infrastructure's shareholder returns expected early 2026 as wind-down continues

(Sharecast News) - Closed-end investment company Digital 9 Infrastructure, which has been implementing a managed wind-down of the company for the past 18 months, reported reported "strong progress" in its plans as losses narrowed significantly in the first half. Following the disposal of SeaEdge UK 1 in June for £10.3m, the completion of the EMIC-1 divestment for $43m in May and the announcement of the Aqua Comms divestment in January for $44.5m, the first phase of Digital 9's wind-down is now "largely complete", according to chair Eric Sanderson.

Sanderson said the company financial position had also "stabilised", following the full repayment of its revolving credit facility, which stood at £53m at the end of December.

"We have a platform to maximise shareholder value over time, following the full repayment of the RCF and completion of the Aqua Comms sale expected by the end of the year. With value-enhancing initiatives underway at Elio Networks and key decisions in relation to contract renewals regarding Arqiva's DTT business to take place in 2027, significant value remains to be unlocked," Sanderson said.

First capital returns to shareholders are expected in early 2026, the company said.

Net asset value shrank to £283.1m by 30 June, down from £297.3m as of 31 December and £403m a year earlier. EBITDA decreased by 3% to £166m, while losses per share fell to 1.7p from 19.8p a year earlier.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.